GlassScriptPhysician profile
Osvaldo Gonzalez
NPI 1104828748
$30,954.31
in general payments reported to CMS, 2019-2025
52 companies · $3,947 in 2025
The $3,947 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,764 · 2020: $1,721 · 2021: $4,126 · 2022: $8,587 · 2023: $5,224 · 2024: $3,584 · 2025: $3,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,639.42 |
| Education | $116.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $4,698.37 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Mannkind Corporation | $3,371.34 | 2019-2025 | |
| Novo Nordisk INC | $2,367.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $2,353.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,151.40 | 2019-2024 | Farxiga |
| Horizon Therapeutics Plc | $1,781.12 | 2022-2023 | Tepezza |
| Corcept Therapeutics | $1,333.40 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,328.32 | 2019-2025 | Jardiance, Synjardy |
| Insulet Corporation | $1,232.28 | 2019-2025 | Omnipod, Omnipod |
| Cequr Corporation | $1,216.55 | 2023-2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $999.78 | 2019-2025 | Unithroid |
| Dexcom, INC. | $975.98 | 2019-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor |
| Abbvie INC. | $892.74 | 2019-2025 | |
| Abbott Laboratories | $573.74 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $565.13 | 2020-2025 | Gvoke Hypopen, Recorlev |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $494.20 | 2019-2022 | |
| Amgen INC. | $486.34 | 2020-2025 | Evenity, Prolia, Tepezza |
| Ascensia Diabetes Care US INC. | $429.88 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $422.65 | 2022-2025 | |
| Antares Pharma, INC. | $357.41 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Tandem Diabetes Care, INC. | $275.79 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $210.54 | 2023-2024 | |
| Beta Bionics, INC. | $199.95 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Radius Health, INC. | $175.85 | 2019-2024 | Tymlos |
| Amarin Pharma, INC. | $169.27 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $151.13 | 2019 | |
| Recordati_rare_diseases_inc. | $143.19 | 2021-2024 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $138.24 | 2023-2025 | Strensiq |
| Valeritas, INC. | $135.90 | 2019 | |
| Medtronic, INC. | $135.32 | 2021-2025 | Minimed 780g, Inceptiv |
| Ascendis Pharma Endocrinology INC | $133.55 | 2023-2025 | Yorvipath |
| Esperion Therapeutics, INC. | $133.35 | 2021-2025 | Nexletol |
| Senseonics, Incorporated | $97.00 | 2019 | |
| Halozyme INC | $96.12 | 2023 | |
| Madrigal Pharmaceuticals | $87.86 | 2025 | Rezdiffra |
| Acerus Pharmaceuticals Corporation | $80.04 | 2020-2021 | |
| Ibsa Pharma INC. | $75.62 | 2021-2024 | Licart, Tirosint |
| Eusa Pharma (US) LLC | $73.85 | 2022 | |
| Pfizer INC. | $57.84 | 2019-2022 | |
| Amphastar Pharmaceuticals, INC. | $52.64 | 2024-2025 | |
| Lifescan, INC. | $43.13 | 2021-2022 | |
| Smith+Nephew, INC. | $33.68 | 2019-2020 | |
| Nevro Corp. | $30.28 | 2023 | Senza |
| Integra Lifesciences Corporation | $28.73 | 2019 | |
| Coloplast Corp | $28.19 | 2020 | |
| Embecta Corp. | $27.93 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Zealand Pharma US, INC. | $25.05 | 2022 | |
| Clarus Therapeutics INC. | $23.03 | 2021 | |
| Neurocrine Biosciences, INC. | $21.86 | 2025 | |
| Vistapharm, INC. | $13.30 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.79 | 2021 | |
| Alfasigma USA, INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osvaldo Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.